Vimarsana
Biggest News Aggregation in the World

Page 6 - Abbott Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Abbott Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Abbott Diagnostics Today - Breaking & Trending Today

Hematology Diagnostic Devices And Equipment Market Size, Share, Revenue, Trends And Drivers For 2023-2032 - Vimarsana News

Hematology Diagnostic Devices And Equipment Market Size, Share, Revenue, Trends And Drivers For 2023-2032

The Business Research Company's Hematology Diagnostic Devices And Equipment Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032

Immunochemistry Diagnostic Devices And Equipment Market Forecast 2023-32: Market Size, Drivers, Trends & Competitors - Vimarsana News

Immunochemistry Diagnostic Devices And Equipment Market Forecast 2023-32: Market Size, Drivers, Trends & Competitors

The Business Research Company’s Immunochemistry Diagnostic Devices And Equipment Global Market Report 2023 – Market Size, Trends, And Global Forecast 2023-2032

Application of a sex-specific GRACE score in practice - Vimarsana News

Application of a sex-specific GRACE score in practice

We wish to congratulate Florian A Wenzl and colleagues1 for their important analysis and update of the Global Registry of Acute Coronary Events (GRACE) score to address observed differences in the prediction of in-hospital mortality following non-ST-segment elevation acute coronary syndromes between women and men. If this state-of-the-art prediction model is to reduce sex inequalities in care, then additional information is needed to ensure the GRACE 3.0 score is consistently applied in practice.

Oncology Molecular Diagnostics Market Size, Share And Growth Analysis For 2023-2032 - Vimarsana News

Oncology Molecular Diagnostics Market Size, Share And Growth Analysis For 2023-2032

The Business Research Company’s Oncology Molecular Diagnostics Global Market Report 2023 – Market Size, Trends, And Market Forecast 2023-2032

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial - Vimarsana News

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community.